Impact of Diabetes Mellitus on Antithrombotic Management Patterns and Long-Term Clinical Outcomes in Patients With Acute Coronary Syndrome: Insights From the EPICOR Asia Study.
Shaoyi Guan,Xiaoming Xu,Yi Li,Jing Li,Mingzi Guan,Xiaozeng Wang,Quanmin Jing,Yong Huo,Yaling Han
DOI: https://doi.org/10.1161/jaha.119.013476
IF: 6.106
2020-11-11
Journal of the American Heart Association
Abstract:Background Long‐term use of antiplatelet agents after acute coronary syndrome in diabetic patients is not well known. Here, we describe antiplatelet use and outcomes in such patients enrolled in the EPICOR Asia (Long‐Term Follow‐up of Antithrombotic Management Patterns in Acute Coronary Syndrome Patients in Asia) registry. Methods and Results EPICOR Asia is a prospective, observational study of 12 922 patients with acute coronary syndrome surviving to discharge, from 8 countries/regions in Asia. The present analysis included 3162 patients with diabetes mellitus (DM) and 9602 patients without DM. The impact of DM on use of antiplatelet agents and events (composite of death, myocardial infarction, and stroke, with or without any revascularization; individual components, and bleeding) was evaluated. Significant baseline differences were seen between patients with DM and patients without DM for age, sex, body mass index, cardiovascular history, angiographic findings, and use of percutaneous coronary intervention. At discharge, ≈90% of patients in each group received dual antiplatelet therapy. At 2‐year follow‐up, more patients with DM tended to still receive dual antiplatelet therapy (60% versus 56%). DM was associated with increased risk from ischemic but not major bleeding events. Independent predictors of the composite end point of death, myocardial infarction, and stroke in patients with DM were age ≥65 years and use of diuretics at discharge. Conclusions Antiplatelet agent use is broadly comparable in patients with DM and patients without DM, although patients with DM are more likely to be on dual antiplatelet therapy at 2 years. Patients with DM are at increased risk of ischemic events, suggesting an unmet need for improved antithrombotic treatment. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01361386. Nonstandard Abbreviations and Acronyms DAPT dual antiplatelet therapy DM diabetes mellitus EPICOR Long‐Term Follow‐up of Antithrombotic Management Patterns in Acute Coronary Syndrome Patients PoCE patient‐oriented composite end point Clinical Perspective What Is New? Among patients surviving an acute coronary syndrome, ≈90% of both patients with diabetes mellitus (DM) and patients without DM were discharged on dual antiplatelet therapy, but somewhat more patients with DM than patients without DM were on dual antiplatelet therapy at 2 years after discharge (60% versus 56%). Although DM was associated with increased risk of ischemic events during follow‐up, there was minimal impact on risk of major bleeding. Multivariable analysis showed that independent predictors of the composite end point of death, myocardial infarction, and stroke in patients with DM were older age (≥65 years) and use of diuretics at discharge. What Are the Clinical Implications? Despite a higher rate of dual antiplatelet therapy use in patients with DM than patients without DM at 2 years after an acute coronary syndrome, patients with DM were at increased risk of ischemic but not bleeding events, suggesting an unmet need for improved antithrombotic treatment. According to the International Diabetes Federation, in 2015, there were ≈415 million patients worldwide aged 20 to 79 with diabetes mellitus (DM), along with a further 193 million undiagnosed cases. 1 Type 2 DM accounts for up to 90% of all cases, and the prevalence is increasing globally. 1 About half of all deaths in patients with DM are due to cardiovascular disease, 1 the majority resulting from thrombotic events. 2 In addition, patients with DM have a 2‐ to 4‐fold higher risk of recurrent atherothrombotic events and vascular complications than those without DM. 2 Along with oxidative stress, inflam -Abstract Truncated-
cardiac & cardiovascular systems